Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial

OBJECTIVE: Rett syndrome (RTT), commonly caused by methyl‐CpG‐binding protein 2 (MECP2) pathogenic variants, has many comorbidities. Fifty to ninety percent of children with RTT have epilepsy, which is often drug‐resistant. Cannabidivarin (CBDV), a non‐hallucinogenic phytocannabinoid, has shown bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurley, Ellen N., Ellaway, Carolyn J., Johnson, Alexandra M., Truong, Linda, Gordon, Rebecca, Galettis, Peter, Martin, Jennifer H., Lawson, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544893/
https://www.ncbi.nlm.nih.gov/pubmed/35364618
http://dx.doi.org/10.1111/epi.17247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544893/
https://www.ncbi.nlm.nih.gov/pubmed/35364618
http://dx.doi.org/10.1111/epi.17247

Ejemplares similares